Cue Biopharma, Inc.
Cue Biopharma, Inc. Q3 FY2022 earnings call
November 14, 2022 · fiscal period ended 2022-09
EPS · actual vs est
Revenue · actual vs est
Summary
Generated 2022-11-14
Management highlights
Dan Passeri provided an overview of the company's competitive and strategic positioning based on data from CUE-101 monotherapy and combination trials with KEYTRUDA. Anish Suri discussed the mechanistic features of the Immuno-STAT platform, including the CUE-100 series, its selectivity for tumor-specific T cells, and favorable manufacturability. Ken Pienta and Matteo Levisetti shared clinical data from CUE-101 trials, including monotherapy showing survival trends and combination with KEYTRUDA showing promising response rates. Kerri Millar provided financial updates, mentioning collaboration revenue, R&D and G&A expenses, and the $30M pipe financing to support development into 2024.
Segment performance
There are no traditional product segments with revenue contribution as the company is in the early stages of clinical development. The focus is on the CUE-101 and CUE-102 programs under its Immuno-STAT platform for cancer immunotherapy.
Guidance
The $30M pipe financing will allow support for development of the Immuno-STAT platform into 2024. CUE-101 monotherapy expansion cohort is expected to have mature median overall survival data by end of 2022 with potential registration trial defined mid-2023. CUE-101 plus KEYTRUDA combination expansion cohort anticipates preliminary overall response rate in Q2 2023 with potential registration trial defined in H2 2023. CUE-102 monotherapy dose escalation trial ongoing with data expected mid-2023.
Risks
No detailed discussion of specific risks in the transcript, but general risks associated with clinical trial development, regulatory approvals, and market acceptance apply.
Q&A highlights
Q: Reni Benjamin asked about median duration of response for monotherapy and combo, and neoadjuvant study details.
A: Ken Pienta and Matteo Levisetti responded.
Q: Stephen Willey asked about duration of response for combo patient and NeoStat.
A: Matteo Levisetti and Anish Suri responded.
Q: Mark Breidenbach asked about registrational trials and T cell expansion in combo.
A: Dan Passeri, Matteo Levisetti, and Anish Suri responded.
Q: Unidentified Analyst asked about comparing CUE-101 to other therapies and advancing monotherapy.
A: Matteo Levisetti responded.
Q: Ted Tenthoff asked about 102's opportunity.
A: Dan Passeri and Matteo Levisetti responded.
Key numbers
Reported versus consensus
Earnings calendar feed
| Metric | Reported | Consensus | Delta | Prior year |
|---|---|---|---|---|
| EPS | $-0.31 | $-0.38 | +18.4% | — |
| Revenue | $68,000 | $513,500 | -86.8% | — |
Transcript
November 14, 2022Full transcript unavailable for redistribution
The structured summary above covers the available call sections. Full transcript text is not included on this page.
Continue exploring
Prior quarters
This page presents the stored structured earnings-call summary and deterministic earnings calendar values. How this is generated. For informational purposes only; not investment advice.